{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:55:58Z","timestamp":1791413758897,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77415-1","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:44:46Z","timestamp":1788803086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I\/II CHORUS trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0294-8749","authenticated-orcid":false,"given":"Narek","family":"Shaverdian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3018","authenticated-orcid":false,"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Toumbacaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4492-4872","authenticated-orcid":false,"given":"Jasme","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4658-3777","authenticated-orcid":false,"given":"Karmelina","family":"Charalambous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna Y.","family":"Gelblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1813-8532","authenticated-orcid":false,"given":"Fernando C.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie F.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gewanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Y.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-7091","authenticated-orcid":false,"given":"Abraham J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-3694","authenticated-orcid":false,"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-9510","authenticated-orcid":false,"given":"Helena","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Preeshagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9464-3984","authenticated-orcid":false,"given":"Paul","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsheen","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-5000","authenticated-orcid":false,"given":"Michael","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-584X","authenticated-orcid":false,"given":"Ronglai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-849X","authenticated-orcid":false,"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-7945","authenticated-orcid":false,"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-9982","authenticated-orcid":false,"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"77415_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"77415_CR2","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.  N. Engl. J. Med. 379, 2342\u20132350 (2018).","journal-title":"N. Engl. J. Med."},{"key":"77415_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.radonc.2019.11.015","volume":"144","author":"N Shaverdian","year":"2020","unstructured":"Shaverdian, N. et al. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. Radiother. Oncol. 144, 101\u2013104 (2020).","journal-title":"Radiother. Oncol."},{"key":"77415_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cllc.2023.03.013","volume":"24","author":"N Yegya-Raman","year":"2023","unstructured":"Yegya-Raman, N. et al. Utilization and factors precluding receipt of checkpoint inhibitor consolidation for stage iii nsclc in a large us academic health system. Clin. lung cancer 24, 474\u2013482 (2023).","journal-title":"Clin. lung cancer"},{"key":"77415_CR5","unstructured":"Bradley, J. D. et al. Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non\u2013Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. J. Clin. Oncol. 0:JCO-25-00036 10.1200\/JCO-25-00036 (2025)."},{"key":"77415_CR6","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jtho.2025.09.020","volume":"20","author":"JM Varlotto","year":"2025","unstructured":"Varlotto, J. M. et al. PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC. J. Thorac. Oncol. 20, S4\u2013S5 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"77415_CR7","doi-asserted-by":"crossref","unstructured":"Peters, S. et al. 65O CheckMate 73L: Phase III study comparing nivolumab (N)\u00a0+\u00a0concurrent chemoradiotherapy (CCRT) followed by N\u00a0\u00b1\u00a0ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC. Immuno-Oncol. Technol. 24, 10.1016\/j.iotech.2024.100808 (2024).","DOI":"10.1016\/j.iotech.2024.100808"},{"key":"77415_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).","journal-title":"Nat. Commun."},{"key":"77415_CR9","doi-asserted-by":"publisher","unstructured":"Huang, J. et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat. Cancer 6, 1676\u20131692 https:\/\/doi.org\/10.1038\/s43018-025-01018-w (2025).","DOI":"10.1038\/s43018-025-01018-w"},{"key":"77415_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9330","volume":"7","author":"RC Hsieh","year":"2022","unstructured":"Hsieh, R. C. et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci. Immunol. 7, eabl9330 (2022).","journal-title":"Sci. Immunol."},{"key":"77415_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijrobp.2022.06.054","volume":"114","author":"Y Chiang","year":"2022","unstructured":"Chiang, Y. et al. Tumor-Derived C-C Motif Ligand 2 induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment. Int. J. Radiat. Oncol. Biol. Phys. 114, 321\u2013333 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"77415_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1126\/science.aaf7532","volume":"354","author":"B Hu","year":"2016","unstructured":"Hu, B. et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. Science 354, 765\u2013768 (2016).","journal-title":"Science"},{"key":"77415_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.460","volume":"8","author":"YG Liu","year":"2017","unstructured":"Liu, Y. G. et al. NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages. Cell Death Dis. 8, e2579 (2017).","journal-title":"Cell Death Dis."},{"key":"77415_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12931-023-02331-7","volume":"24","author":"X Rao","year":"2023","unstructured":"Rao, X. et al. Activation of NLRP3 inflammasome in lung epithelial cells triggers radiation-induced lung injury. Respir. Res 24, 25 (2023).","journal-title":"Respir. Res"},{"key":"77415_CR15","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.4049\/jimmunol.0901511","volume":"183","author":"Y Carmi","year":"2009","unstructured":"Carmi, Y. et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183, 4705\u20134714 (2009).","journal-title":"J. Immunol."},{"key":"77415_CR16","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1158\/0008-5472.CAN-07-2354","volume":"67","author":"SK Bunt","year":"2007","unstructured":"Bunt, S. K. et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019\u201310026 (2007).","journal-title":"Cancer Res."},{"key":"77415_CR17","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1002\/eji.201041037","volume":"40","author":"M Elkabets","year":"2010","unstructured":"Elkabets, M. et al. IL-1\u03b2 regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40, 3347\u20133357 (2010).","journal-title":"Eur. J. Immunol."},{"key":"77415_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-20-0431","volume":"9","author":"M Kiss","year":"2021","unstructured":"Kiss, M. et al. IL1\u03b2 promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D. Cancer Immunol. Res. 9, 309\u2013323 (2021).","journal-title":"Cancer Immunol. Res"},{"key":"77415_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2767-9764.CRC-24-0490","volume":"5","author":"BJ Solomon","year":"2025","unstructured":"Solomon, B. J. et al. The Impact of the Tumor Microenvironment on the Effect of IL-1\u03b2 Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Res Commun. 5, 632\u2013646 (2025).","journal-title":"Cancer Res Commun."},{"key":"77415_CR20","volume":"1","author":"EB Garon","year":"2020","unstructured":"Garon, E. B., Chih-Hsin Yang, J. & Dubinett, S. M. The Role of Interleukin 1\u03b2 in the Pathogenesis of Lung Cancer. JTO Clin. Res Rep. 1, 100001 (2020).","journal-title":"JTO Clin. Res Rep."},{"key":"77415_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01566-5","volume":"8","author":"H Liang","year":"2017","unstructured":"Liang, H. et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat. Commun. 8, 1736 (2017).","journal-title":"Nat. Commun."},{"key":"77415_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","volume":"27","author":"DH Aggen","year":"2021","unstructured":"Aggen, D. H. et al. Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clin. Cancer Res. 27, 608 (2021).","journal-title":"Clin. Cancer Res."},{"key":"77415_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"77415_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00898-8","volume":"13","author":"DWY Tsui","year":"2021","unstructured":"Tsui, D. W. Y. et al. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Med. 13, 96 (2021).","journal-title":"Genome Med."},{"key":"77415_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24109-5","volume":"12","author":"A Rose Brannon","year":"2021","unstructured":"Rose Brannon, A. et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat. Commun. 12, 3770 (2021).","journal-title":"Nat. Commun."},{"key":"77415_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","volume":"9","author":"L Boscolo Bielo","year":"2023","unstructured":"Boscolo Bielo, L. et al. Variant allele frequency: a decision-making tool in precision oncology? Trends Cancer 9, 1058\u20131068 (2023).","journal-title":"Trends Cancer"},{"key":"77415_CR27","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst, R. S. et al. COAST: an open-label, phase ii, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage iii non\u2013small-cell lung cancer. J. Clin. Oncol. 40, 3383\u20133393 (2022).","journal-title":"J. Clin. Oncol."},{"key":"77415_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39874-8","volume":"14","author":"JV Alessi","year":"2023","unstructured":"Alessi, J. V. et al. Impact of TMB\/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC. Nat. Commun. 14, 4238 (2023).","journal-title":"Nat. Commun."},{"key":"77415_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2025.101727","volume":"10","author":"ES Lebow","year":"2025","unstructured":"Lebow, E. S. et al. Cell-free circulating tumor DNA for noninvasive molecular profiling among patients undergoing definitive chemoradiation for locally advanced lung cancer. Adv. Radiat. Oncol. 10, 101727 (2025).","journal-title":"Adv. Radiat. Oncol."},{"key":"77415_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","volume":"1","author":"EJ Moding","year":"2020","unstructured":"Moding, E. J. et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat. Cancer 1, 176\u2013183 (2020).","journal-title":"Nat. Cancer"},{"key":"77415_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","volume":"34","author":"S Senan","year":"2016","unstructured":"Senan, S. et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 34, 953\u2013962 (2016).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"77415_CR32","doi-asserted-by":"crossref","unstructured":"Ahn, J. S. et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non\u2013Small-Cell Lung Cancer: KCSG-LU05-04. 33, 2660\u20132666 (2015).","DOI":"10.1200\/JCO.2014.60.0130"},{"key":"77415_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3857\/roj.2019.00640","volume":"38","author":"C Kang","year":"2020","unstructured":"Kang, C., Jeong, S.-Y., Song, S. Y. & Choi, E. K. The emerging role of myeloid-derived suppressor cells in radiotherapy. Radiat. Oncol. J. 38, 1\u201310 (2020).","journal-title":"Radiat. Oncol. J."},{"key":"77415_CR34","doi-asserted-by":"publisher","unstructured":"Paz-Ares, L. et al. 1587TiPCANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC). Ann. Oncol. 30, https:\/\/doi.org\/10.1093\/annonc\/mdz260.109 (2019).","DOI":"10.1093\/annonc\/mdz260.109"},{"key":"77415_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.23.00910","volume":"42","author":"EB Garon","year":"2024","unstructured":"Garon, E. B. et al. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 42, 180\u2013191 (2024).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"77415_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107451","volume":"189","author":"L Paz-Ares","year":"2024","unstructured":"Paz-Ares, L. et al. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung cancer (Amst., Neth.) 189, 107451 (2024).","journal-title":"Lung cancer (Amst., Neth.)"},{"key":"77415_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.23.00980","volume":"42","author":"DSW Tan","year":"2024","unstructured":"Tan, D. S. W. et al. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 42, 192\u2013204 (2024).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"77415_CR38","doi-asserted-by":"publisher","first-page":"18584","DOI":"10.1073\/pnas.1901562116","volume":"116","author":"AJ Wisdom","year":"2019","unstructured":"Wisdom, A. J. et al. Neutrophils promote tumor resistance to radiation therapy. Proc. Natl. Acad. Sci. USA 116, 18584\u201318589 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77415-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:41:29Z","timestamp":1791412889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77415-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77415"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77415-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.S.: Grant\/research funding; Novartis, Amgen, AstraZeneca, Humanetics Corporation. M.O.: Grant\/research funding; LUNGevity, Druckenmiller Foundation. Honoraria: Pfizer, MJH Associates, ASTRO, Jazz Pharmaceuticals. Uncompensated; Mesothelioma Applied Research Foundation. Professional Services and Activities: Mesothelioma Applied Research Foundation. N.T.: None. J.L.: None. K.C.: None. D.G.: None. F.S.: Compensation\/Payment; Bayer. A.F.S.: Stock; ArcellX, Doximity. R.G.: None. B.M.: None. J.Y.S.: None. A.J.W.: None. C.B.S. II: leadership or fiduciary role for the American Society for Radiation Oncology, Proton Collaborative Group, American Radium Society, and the Particle Therapy Co-Operative Group. A.R.: Grant\/research funding; Varian Medical Systems, Boehringer Ingelheim, AstraZeneca, Merck, Pfizer. Honoraria: AstraZeneca, Merck. Board Member; International Mesothelioma Interest Group. Vice President of ITMIG; International Thymic Malignancies Interest Group. N.Y.L.: Advisory boards of Merck, Merck Serono, Nanotiotix, Galera, LEO SAB, GSK She has stock options from LEO SAB. M.S.G.: None H.Y: consultant or advisor for AbbVie, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo, Janssen, Novocure, and Taiho Oncology; has received research funding (institution) from Astellas Pharma, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Erasca, Janssen, Lilly, Novartis, Pfizer, and Systimmune; and reports other relationships with Astellas Pharma B.D.: stock and other ownerships with CVS Health, Lilly, Roche\/Genentech; consulting or advisory role with Varian Medical Systems and I-MAB Biopharma M.G.K.: Compensation\/Payment; i3 Health, Merus, MJH Associates. consulting fees; AstraZeneca, BerGenBio, Pfizer, Daiichi-Sankyo, Sanofi, Novartis. I.P.: None. P.P.: Grant\/research funding; Boehringer Ingelheim, Novartis. advisory\/consulting fee; Takeda, AstraZeneca, Janssen, CrownBio, Bicara, Mirati, EMD Serono. J.E.: None. A.I.: None. K.N.: None. M.B.: Compensation\/Payment; AstraZeneca, Paige.AI, Inc. Intellectual Property Rights; SOPHiA GENETICS S.A. R. Shah: None. R. Shen: None. P.W.: None. Z.Z.: None. D.R.G.: Compensation\/Payment; AstraZeneca, Grail, Johnson & Johnson, Medtronic, Varian Medical Systems. J.C.: Grant\/research funding; AstraZeneca, Bristol-Myers Squibb, Merck, Genentech, Novartis, Beigene. consulting fees; AstraZeneca, Bristol-Myers Squibb, Merck, Genentech, Regeneron\/Sanofi, Guardant Health, Janssen, Lilly, Hoffmann-La Roche Ltd.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10586"}}